Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 11;13:17. doi: 10.1186/s13326-022-00272-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — Flowchart of the selection process of the adverse drug event (ADE) phenotypes. The selection of the final list of ADE phenotypes started with the list literature-based discovery that has identified drug-drug interactions (DDIs) due to interactions among five Cytochrome P450 (CYPs) enzymes, including CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A. This step was followed by the ADEs eligibility evaluation through evidence of drugs-ADEs linkage in the Side Effect Resource (SIDER) database and expert manual review to include the final list of ADE phenotypes of interest